Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Energy policy: The rebound effect is overplayed.

Gillingham K, Kotchen MJ, Rapson DS, Wagner G.

Nature. 2013 Jan 24;493(7433):475-6. doi: 10.1038/493475a. No abstract available.

PMID:
23344343
2.

A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population.

Bowman M, Hopman WM, Rapson D, Lillicrap D, Silva M, James P.

Pediatr Blood Cancer. 2010 Jul 15;55(1):171-3. doi: 10.1002/pbc.22429.

PMID:
20213845
3.

The prevalence of symptomatic von Willebrand disease in primary care practice.

Bowman M, Hopman WM, Rapson D, Lillicrap D, James P.

J Thromb Haemost. 2010 Jan;8(1):213-6. doi: 10.1111/j.1538-7836.2009.03661.x. Epub 2009 Oct 23. No abstract available.

4.

Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.

Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P.

J Thromb Haemost. 2008 Dec;6(12):2062-6. doi: 10.1111/j.1538-7836.2008.03182.x. Epub 2008 Oct 4.

5.

Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: an observational study.

Saberi F, Heyland D, Lam M, Rapson D, Jeejeebhoy K.

JPEN J Parenter Enteral Nutr. 2008 May-Jun;32(3):227-35. doi: 10.1177/0148607108316195.

PMID:
18443133
6.

The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.

Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting PJ, Rapson D, Lillicrap D, James P.

J Thromb Haemost. 2008 Jan;6(1):90-6. Epub 2007 Oct 8.

7.

Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.

James PD, Notley C, Hegadorn C, Poon MC, Walker I, Rapson D, Lillicrap D; Association of Hemophilia Clinic Directors of Canada.

J Thromb Haemost. 2007 Sep;5(9):1914-22. Epub 2007 Jun 26.

8.

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D.

Blood. 2007 Jan 1;109(1):145-54.

9.

The value of genetic testing for type 2B Von Willebrand disease.

Roland K, Rapson D, Lillicrap D, James P.

Clin Lab Haematol. 2006 Feb;28(1):17-21.

PMID:
16430455
10.

A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.

O'Brien LA, Sutherland JJ, Hegadorn C, Benford K, Racz H, Rapson D, Hough C, Lillicrap D.

J Thromb Haemost. 2004 Jul;2(7):1135-42.

11.

Extramedullary hematopoiesis in a pyogenic granuloma.

Rowlands CG, Rapson D, Morell T.

Am J Dermatopathol. 2000 Oct;22(5):434-8.

PMID:
11048980
12.

Capnocytophaga canimorsus, a potential emerging microorganism in splenectomized patients.

Yu RK, Shepherd LE, Rapson DA.

Br J Haematol. 2000 Jun;109(4):679. No abstract available.

PMID:
10929015
13.

Sensitivity of routine blood bank methods for the detection of anti-D as determined during proficiency testing.

Pinkerton PH, Zuber ED, Barr RM, Croucher BE, Quantz MC, Rapson DA, Wood DE, Crockford J, Moore BP.

Am J Clin Pathol. 1984 Sep;82(3):326-9.

PMID:
6431798

Supplemental Content

Loading ...
Support Center